Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epigenesis, Genetic | 10 | 2020 | 144 | 3.930 |
Why?
|
| DNA Methylation | 14 | 2022 | 149 | 3.560 |
Why?
|
| Osteoarthritis, Knee | 5 | 2024 | 24 | 3.190 |
Why?
|
| Osteoarthritis, Hip | 3 | 2020 | 12 | 1.710 |
Why?
|
| Microbiota | 2 | 2022 | 79 | 1.370 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 121 | 1.350 |
Why?
|
| Cartilage, Articular | 4 | 2024 | 43 | 1.320 |
Why?
|
| Osteoarthritis | 2 | 2018 | 35 | 1.170 |
Why?
|
| Lupus Erythematosus, Systemic | 9 | 2015 | 986 | 1.040 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 162 | 0.960 |
Why?
|
| Epigenomics | 3 | 2020 | 29 | 0.910 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2015 | 99 | 0.840 |
Why?
|
| Probiotics | 1 | 2022 | 16 | 0.790 |
Why?
|
| Biological Products | 1 | 2022 | 60 | 0.780 |
Why?
|
| Metagenome | 1 | 2020 | 50 | 0.680 |
Why?
|
| Disease | 1 | 2020 | 15 | 0.680 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 73 | 0.660 |
Why?
|
| RNA, Untranslated | 2 | 2020 | 9 | 0.660 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 318 | 0.640 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 301 | 0.630 |
Why?
|
| Gene Editing | 1 | 2018 | 18 | 0.590 |
Why?
|
| Bone Remodeling | 1 | 2017 | 11 | 0.590 |
Why?
|
| Humans | 27 | 2022 | 26856 | 0.570 |
Why?
|
| Genome-Wide Association Study | 4 | 2016 | 238 | 0.510 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 12 | 0.480 |
Why?
|
| Hip Joint | 1 | 2014 | 18 | 0.480 |
Why?
|
| Histone Code | 3 | 2020 | 4 | 0.470 |
Why?
|
| Histones | 1 | 2015 | 90 | 0.470 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 100 | 0.460 |
Why?
|
| Female | 16 | 2024 | 14462 | 0.400 |
Why?
|
| Animals | 9 | 2024 | 9954 | 0.390 |
Why?
|
| Knee Joint | 2 | 2022 | 40 | 0.380 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 274 | 0.360 |
Why?
|
| Disease Progression | 2 | 2022 | 450 | 0.330 |
Why?
|
| CD27 Ligand | 3 | 2009 | 3 | 0.330 |
Why?
|
| Male | 10 | 2024 | 12866 | 0.320 |
Why?
|
| Middle Aged | 8 | 2020 | 6825 | 0.310 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 22 | 0.310 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 22 | 0.300 |
Why?
|
| Biomarkers | 2 | 2022 | 731 | 0.300 |
Why?
|
| Sulfonamides | 1 | 2008 | 69 | 0.290 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 13 | 0.290 |
Why?
|
| Mice | 6 | 2024 | 4402 | 0.280 |
Why?
|
| Aged | 6 | 2020 | 5169 | 0.250 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 130 | 0.220 |
Why?
|
| Sex Characteristics | 1 | 2024 | 162 | 0.220 |
Why?
|
| Models, Genetic | 3 | 2019 | 123 | 0.210 |
Why?
|
| Adult | 8 | 2015 | 7389 | 0.200 |
Why?
|
| Models, Animal | 1 | 2022 | 128 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 1999 | 67 | 0.190 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2013 | 15 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 1474 | 0.180 |
Why?
|
| Liver Transplantation | 2 | 1998 | 51 | 0.180 |
Why?
|
| Wound Healing | 1 | 2021 | 113 | 0.180 |
Why?
|
| Genetic Variation | 2 | 2020 | 229 | 0.180 |
Why?
|
| Classification | 1 | 2020 | 15 | 0.180 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2020 | 29 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 252 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 624 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2020 | 38 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2020 | 104 | 0.170 |
Why?
|
| Paracentesis | 1 | 1999 | 5 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 72 | 0.170 |
Why?
|
| Peritonitis | 1 | 1999 | 15 | 0.170 |
Why?
|
| Ascites | 1 | 1999 | 19 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 262 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 1999 | 58 | 0.170 |
Why?
|
| Radiography | 1 | 2019 | 200 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 1999 | 56 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 664 | 0.160 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1998 | 3 | 0.160 |
Why?
|
| Hydrothorax | 1 | 1998 | 3 | 0.160 |
Why?
|
| Helicobacter pylori | 1 | 1998 | 17 | 0.150 |
Why?
|
| Helicobacter Infections | 1 | 1998 | 16 | 0.150 |
Why?
|
| Peptic Ulcer | 1 | 1998 | 11 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 400 | 0.150 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1998 | 4 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 391 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 34 | 0.150 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2017 | 6 | 0.150 |
Why?
|
| RANK Ligand | 1 | 2017 | 19 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 43 | 0.150 |
Why?
|
| Osteoblasts | 1 | 2017 | 35 | 0.140 |
Why?
|
| Autoantibodies | 3 | 2013 | 466 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 1998 | 43 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2017 | 40 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 54 | 0.140 |
Why?
|
| Cartilage | 1 | 2017 | 33 | 0.140 |
Why?
|
| Genetic Therapy | 1 | 2018 | 116 | 0.140 |
Why?
|
| MicroRNAs | 2 | 2017 | 278 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2017 | 395 | 0.120 |
Why?
|
| Haplotypes | 2 | 2013 | 279 | 0.120 |
Why?
|
| Lupus Nephritis | 1 | 2015 | 99 | 0.120 |
Why?
|
| Kidney | 1 | 2015 | 274 | 0.110 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2013 | 860 | 0.100 |
Why?
|
| Interferon Type I | 1 | 2013 | 55 | 0.100 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cytosine | 1 | 2011 | 6 | 0.090 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2017 | 1339 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 27 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 323 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2011 | 54 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2011 | 134 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 143 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 1927 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 332 | 0.080 |
Why?
|
| Uric Acid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 44 | 0.080 |
Why?
|
| Interferons | 1 | 2008 | 68 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2009 | 203 | 0.070 |
Why?
|
| Apoptosis | 1 | 2011 | 737 | 0.070 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2007 | 7 | 0.070 |
Why?
|
| Antibodies, Antinuclear | 1 | 2008 | 181 | 0.070 |
Why?
|
| Ribonucleoproteins | 1 | 2008 | 152 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2007 | 282 | 0.070 |
Why?
|
| Risk Factors | 4 | 2013 | 2017 | 0.060 |
Why?
|
| Base Sequence | 1 | 2007 | 573 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 1998 | 981 | 0.060 |
Why?
|
| Prospective Studies | 2 | 1999 | 1219 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1036 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2013 | 969 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2024 | 165 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 75 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 701 | 0.050 |
Why?
|
| Complement Inactivating Agents | 1 | 2020 | 3 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 74 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 188 | 0.040 |
Why?
|
| Norfloxacin | 1 | 1999 | 4 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 1999 | 11 | 0.040 |
Why?
|
| Hepatitis C | 1 | 1999 | 38 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 487 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1999 | 37 | 0.040 |
Why?
|
| Obesity | 1 | 2024 | 647 | 0.040 |
Why?
|
| Hypertension, Portal | 1 | 1998 | 5 | 0.040 |
Why?
|
| Safety | 1 | 1998 | 31 | 0.040 |
Why?
|
| Bismuth | 1 | 1998 | 2 | 0.040 |
Why?
|
| Antacids | 1 | 1998 | 6 | 0.040 |
Why?
|
| Tetracycline | 1 | 1998 | 4 | 0.040 |
Why?
|
| Naproxen | 1 | 1998 | 11 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 1999 | 79 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1998 | 43 | 0.040 |
Why?
|
| Metronidazole | 1 | 1998 | 16 | 0.040 |
Why?
|
| Pyelonephritis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Primary Health Care | 1 | 1999 | 143 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 72 | 0.040 |
Why?
|
| Recurrence | 1 | 1998 | 316 | 0.040 |
Why?
|
| Survival Rate | 1 | 1998 | 407 | 0.040 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Liver | 1 | 1998 | 415 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1998 | 465 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 95 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 496 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 1998 | 605 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2013 | 6 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 1998 | 2267 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1998 | 2444 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 405 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 437 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 10 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 182 | 0.020 |
Why?
|
| CD11a Antigen | 1 | 2008 | 2 | 0.020 |
Why?
|
| Methylation | 1 | 2008 | 21 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2008 | 12 | 0.020 |
Why?
|
| Doxycycline | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 55 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2008 | 114 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 276 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 664 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 544 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 645 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2584 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1394 | 0.010 |
Why?
|
| Hepatitis C Antibodies | 1 | 1999 | 6 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1999 | 10 | 0.010 |
Why?
|